Skip to main content
. Author manuscript; available in PMC: 2011 Dec 16.
Published in final edited form as: Vaccine. 2010 Sep 15;29(2):357–362. doi: 10.1016/j.vaccine.2010.08.099

Figure 3. TNFα and IFNγ contribute to the increased survival mediated by immunization with recombinant F1-V fusion protein after pulmonary exposure to fully virulent pgm-positive Y. pestis.

Figure 3

Wild-type C57BL/6 mice were immunized by subcutaneous administration of 2.9 ug rF1V fusion protein in alhydrogel adjuvant (alum) and boosted 28 days later. Control mice received only alum. On day 53, mice received either intraperitoneal injections of neutralizing mAb specific for TNFα and IFNγ (aCyt; open symbols) or isotype-matched control mAb (Ctrl; closed symbols). The following day all mice were challenged by whole-body aerosol with 11 LD-50 Y. pestis strain CO92. In comparison with rF1V-immunized mice treated with control mAb, rF1V–immunized mice treated with cytokine-neutralizing mAb exhibited significantly reduced survival (p<0.0004 by Log rank test; n = 10 mice per group).